Stock listing

NASDAQ:PBLS Parabilis Medicines, Inc. Stock

Home listing (NASDAQ) of Parabilis Medicines, Inc.

Follow Parabilis Medicines, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:PBLS

$27.44 USD -1.03 (-3.6%)

Close on Nov 20, 2026

Since Jun 10, 2026 -13.2% · daily closes, Jun 10, 2026 – Nov 20, 2026, adjusted for splits
Day range
$26.50 – $28.52 USDNov 20, 2026
Volume
1.25M sharesNov 20, 2026
Market cap
$3.39B USDAt the close on Nov 20, 2026 · price × 123.7M shares outstanding
Traded on an average day
$30.74M USDMedian day 809,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PBLS · Home$27.44 USD-1.03 (-3.6%)1,246,548$27.09$28.52$26.50$28.47Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PBLS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$27.44-1.03-3.6%$27.09$28.52$26.501,246,548
$28.47+0.22+0.8%$28.22$29.26$27.90602,362
$28.25-0.20-0.7%$28.54$28.54$27.53480,477
$28.45+0.02+0.1%$28.04$28.56$27.63538,172
$28.43+0.74+2.7%$27.63$28.63$26.70555,039
$27.69-1.96-6.6%$29.54$29.88$27.47806,101
$29.65-0.37-1.2%$30.40$30.98$29.29546,014
$30.02-0.35-1.2%$30.49$31.49$29.54502,424
$30.37+1.84+6.4%$29.21$30.85$28.36950,737
$28.53+0.65+2.3%$27.88$28.87$27.11629,323
$27.88-2.48-8.2%$30.13$30.13$27.56920,736
$30.36+1.11+3.8%$30.00$30.83$28.70842,949
$29.25+2.00+7.3%$28.25$29.73$27.90519,401
$27.25-1.07-3.8%$28.13$28.55$26.87702,232
$28.32-0.38-1.3%$28.59$28.74$27.48813,911
$28.70+0.53+1.9%$28.32$30.08$27.19844,724
$28.17+1.66+6.3%$26.24$28.29$26.141,396,094
$26.51+1.48+5.9%$25.00$27.20$24.751,572,596
$25.03+0.59+2.4%$25.01$25.59$23.061,427,693
$24.44-2.48-9.2%$26.74$26.74$23.961,820,900
$26.92-0.93-3.3%$28.03$28.29$26.58911,900
$27.85+0.77+2.8%$27.39$28.48$26.401,392,000
$27.08+1.73+6.8%$25.40$27.93$24.441,495,400
$25.35+2.60+11.4%$22.98$26.24$22.982,142,600
$22.75-2.43-9.7%$25.39$25.71$22.661,115,100
$25.18-0.71-2.7%$25.76$26.44$24.80955,200
$25.89-0.96-3.6%$27.00$27.39$25.73764,900
$26.85-2.10-7.3%$29.45$29.50$26.721,187,800
$28.95+1.47+5.3%$27.38$29.50$26.831,203,000
$27.48-0.61-2.2%$28.15$29.50$27.211,086,600
$28.09-0.73-2.5%$28.42$28.90$26.141,392,600
$28.82-0.04-0.1%$28.78$30.36$27.56994,000
$28.86-0.67-2.3%$29.44$29.73$28.17979,200
$29.53-0.75-2.5%$30.41$30.82$28.56572,500
$30.28-0.16-0.5%$30.34$30.63$28.30881,200
$30.44-1.85-5.7%$31.99$32.63$29.71885,800
$32.29+0.38+1.2%$31.95$32.86$31.20547,100
$31.91-0.66-2.0%$32.84$33.74$31.20453,900
$32.57+1.37+4.4%$31.02$33.76$30.17809,600
$31.20-1.27-3.9%$32.32$32.32$29.571,119,000
$32.47-0.84-2.5%$33.32$33.73$31.061,165,900
$33.31-4.86-12.7%$37.89$37.89$32.951,113,900
$38.17+1.24+3.4%$37.41$38.73$35.51865,500
$36.93-4.80-11.5%$41.58$42.32$34.721,705,600
$41.73+0.85+2.1%$41.01$42.49$39.419,086,000
$40.88+4.00+10.8%$37.51$42.22$37.351,093,200
$36.88+1.16+3.2%$36.19$38.92$35.37971,000
$35.72-0.44-1.2%$36.27$36.38$35.24446,200
$36.16-0.72-2.0%$37.06$37.58$35.60482,300
$36.88+0.56+1.5%$36.90$37.74$36.44364,800
$36.32-2.44-6.3%$38.76$38.77$36.13680,800
$38.76-1.01-2.5%$39.77$40.13$38.33501,200
$39.77-0.65-1.6%$40.97$41.05$39.07564,000
$40.42-0.33-0.8%$40.20$41.19$39.50380,700
$40.75+0.64+1.6%$40.21$40.83$39.12408,300
$40.11+0.64+1.6%$39.73$41.14$38.31363,900
$39.47+0.46+1.2%$39.15$40.00$37.88500,200
$39.01-0.10-0.3%$39.08$40.01$37.77529,900
$39.11-0.18-0.5%$38.96$40.02$38.50316,200
$39.29+0.03+0.1%$39.00$40.19$38.22445,400
$39.26+0.03+0.1%$39.17$39.41$38.09409,100
$39.23+0.80+2.1%$38.52$39.90$38.37286,098
$38.43-0.93-2.4%$39.42$40.56$38.00340,272
$39.36-0.22-0.6%$39.41$40.92$38.95354,600
$39.58-1.74-4.2%$40.70$41.49$39.31205,800
Ticker
NASDAQ:PBLS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Parabilis Medicines, Inc. news

Parabilis Medicines, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
8 in the last 12 months · 8 in all · newest Nov 12, 2026 · oldest 2026
Decks
3 decks · latest September 2026

Where Parabilis Medicines, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PBLS · Home listing · This pageNASDAQUnited StatesUSD
BOATS:PBLSBOATSUnited StatesUSD

Valuation

Price/book 3.4× against a median of 4.1×: 4th lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$2.53B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
3.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Parabilis Medicines, Inc. · NASDAQ:PBLSUS$3.39BUS$2.53Bn/an/an/a3.4×n/a0.0×n/a
Xenon Pharmaceuticals Inc. · NASDAQ:XENEUS$3.64BUS$2.70Bn/an/an/a3.2×n/a0.0×0.80
Relay Therapeutics, Inc. · NASDAQ:RLAYUS$3.56BUS$2.74Bn/a265×n/a4.3×n/a0.0×1.48
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336US$3.56BUS$3.42B7.6×5.1×n/a2.7×69.9%0.0×n/a
Enliven Therapeutics, Inc. · NASDAQ:ELVNUS$3.42BUS$2.54Bn/an/an/a3.9×n/a0.0×0.89
Disc Medicine, Inc. · NASDAQ:IRONUS$3.42BUS$2.80Bn/an/an/a5.7×n/a0.1×0.94
Viridian Therapeutics, Inc. · NASDAQ:VRDNUS$3.40BUS$2.69Bn/a102×n/a5.9×n/a0.4×1.00
Caliway Biopharmaceuticals Co Ltd · TWSE:6919US$3.38BUS$3.27Bn/an/an/a12.7×n/a0.0×n/a
Amylyx Pharmaceuticals, Inc. · NASDAQ:AMLXUS$3.35BUS$2.58Bn/an/an/a4.4×n/a0.0×1.21
Iovance Biotherapeutics, Inc. · NASDAQ:IOVAUS$3.19BUS$2.86Bn/a7.5×n/a3.9×−58.2%0.1×1.62
AbCellera Biologics Inc. · NASDAQ:ABCLUS$3.16BUS$2.53Bn/a37.3×n/a3.0×−218.5%0.1×2.42
Median of the othersUS$3.41BUS$2.72B7.6×37.3×4.1×−58.2%0.0×1.11

Forecasts

7 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
41.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.42 · 2 analysts
Revenue, year to Dec 2026
979.2K · 5 analysts

Team and board

Officers

OfficerRole
Mathai MammenChairman, CEO and President
Thomas KotarakosChief Financial Officer
Alan M. SebulskyPresident, Apothecary Capital Management, Inc
Teresa JurgensenExecutive Vice President, General Counsel
John McGeeScientific Co-Founder and Executive Vice President, Head of Platform
Jonathan HurovExecutive Vice President, Discovery Biology
Marie NguyenSenior Vice President, Head of Clinical Development
Markus HaeberleinExecutive Vice President, Discovery Science
Sheryl JacobsSenior Vice President, Development Operations
Hannah WalterEnterprise Strategic Operations, Chief of Staff to the CEO
Helen HoChief Business and Strategy Officer
Kristen StantsChief People Officer
Rick KlausnerFounder and Chief Scientist Altos Labs, Inc.
Rohin MhatreChief Technical Operations Officer

Board

DirectorRole
Alexis BorisyLead Independent Director; Chairman, Nextech Invest; Chairman, Curie.Bio
Mathai MammenChairman, CEO and President
Craig L. TendlerDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−6.6%
Q2 2026Aug 13, 2026 · Before open−4.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck32 slidesSeptember 2026
Earnings Presentation (August 2026)Earnings32 slidesAug 13, 2026
Technical Presentation (October 2025)Technical17 slidesOctober 2025

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$770.5M raised · US$20 a share · Leerink Partners +4
Dealers: Leerink Partners (co-lead), BofA Securities (co-lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead), LifeSci Capital
Jun 11, 2026
Private placement of common stock
Closed: US$75M raised · US$18 a share
Buyers: Regeneron Pharmaceuticals, Inc. (4,166,666 shares of common stock at $18.00 per share)
Jun 11, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$20.00 a share on Jun 9, 2026.

Price
US$20.00 a share
Shares offered
33,500,000 shares of common stock
Offering size
US$670 million
Underwriters' option
Up to 5,025,000 more shares
Listing
PBLS on the Nasdaq Global Select Market
Underwriters
Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, LifeSci Capital · In the order on the cover
Shares delivered
On or about Jun 11, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceApr 2, 2026
Filed publiclyMay 19, 2026
Amended 3 timesNewest Jun 9, 2026
Shares registered with an exchangeJun 5, 2026
Declared effective by the SECJun 9, 2026
Final prospectus, with the priceJun 10, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Jun 10, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue00
Research and development125.6M100.8M
Selling, general and administrative26.5M25.3M
Operating income-152.1M-126.1M
Depreciation and amortization2.50M2.10M
EBITDA-149.6M-124.0M
Interest expense1.52M1.49M
Income before tax-145.9M-117.9M
Net income-145.9M-117.9M
Earnings per share, basic-1.23-1.00

Balance sheet

LineFY2025FY2024
Cash and equivalents27.7M47.3M
Short-term investments040.7M
Receivables360.0K
Current assets29.4M92.2M
Total assets80.8M149.3M
Accounts payable17.3M9.51M
Current liabilities56.8M32.4M
Long-term debt12.8M
Total debt58.7M66.2M
Total liabilities97.3M92.8M
Shareholders' equity-16.5M56.4M
Shares outstanding118.1M118.1M

Cash flow

LineFY2025FY2024
Cash from operations-123.7M-103.6M
Capital spending-306.0K-879.0K
Free cash flow-124.0M-104.5M
Cash from investing39.8M30.2M
Cash from financing64.4M78.1M
Share buybacks-62.0K-494.0K
Change in cash-19.6M4.70M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
8-K · Current reportNov 5, 2026Material contractSEC
8-K · Current reportSep 15, 2026Current reportSEC
8-K · Current reportSep 2, 2026Management or board changeSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 25, 2026Insider tradeSEC
8-K · Current reportAug 25, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
All 65 filings
FilingDateTypeFiled with
8-K · Current reportAug 13, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
4 · Change in ownershipJul 22, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 29, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeJun 18, 2026Big-stake noticeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Material contractSEC
S-8 · Registration statement for employee plansJun 10, 2026Offer documentSEC
424B4 · ProspectusJun 10, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 10, 2026Other filingsSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
FWP · Free writing prospectusJun 9, 2026Offer documentSEC
S-1MEF · Registration of more shares for the same offeringJun 9, 2026Offer documentSEC
CERT · Exchange's certificate of listingJun 9, 2026Other filingsSEC
S-1/A · Registration statement, amendedJun 9, 2026Offer documentSEC
8-A12B · Registration of shares for listing on an exchangeJun 5, 2026Other filingsSEC
S-1/A · Registration statement, amendedJun 4, 2026Offer documentSEC
S-1/A · Registration statement, amendedMay 27, 2026Offer documentSEC
S-1 · Registration statementMay 19, 2026Offer documentSEC
DRS · Draft registration statementApr 2, 2026Offer documentSEC
DDec 2, 2022Other filingsSEC
DJan 5, 2021Other filingsSEC
D/AMay 16, 2018Other filingsSEC
DFeb 14, 2018Other filingsSEC
D/AAug 22, 2017Other filingsSEC
DJun 7, 2016Other filingsSEC
DNov 13, 2015Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Parabilis Medicines, Inc.’s releases · as of Jun 11, 2026

Common shares
123,676,615
Fully diluted
123,676,615

Fully diluted

LineShares
Common shares123,676,615

Share count over time

CountShares
Nov 22, 2026123,676,615

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Ra Capital Management, L.P.29.2M23.6%US$942MSep 30, 2026
Fidelity10.9M8.8%US$337MSep 30, 2026
ARCH Venture Management, LLC6.41M5.2%US$207MSep 30, 2026
venBio Partners LLC5.27M4.3%US$170MSep 30, 2026
Alphabet Inc.4.92M4.0%US$159MSep 30, 2026
Nextech Invest Ltd.4.66M3.8%US$151MSep 30, 2026
Cormorant Asset Management, LP4.62M3.7%US$149MSep 30, 2026
Regeneron Pharmaceuticals, Inc.4.17M3.4%US$135MSep 30, 2026
Vanguard3.41M2.8%US$110MSep 30, 2026
Janus Henderson3.28M2.6%US$106MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Siren, L.L.C.2.99M2.4%US$96.6MSep 30, 2026
BlackRock2.79M2.3%US$90.1MSep 30, 2026
Farallon Capital Management, L.L.C.2.37M1.9%US$76.5MSep 30, 2026
Frazier Life Sciences Management, L.P.2.33M1.9%US$75.3MSep 30, 2026
Deerfield Management Company, L.P.1.88M1.5%US$60.7MSep 30, 2026
Soleus Capital Management, L.P.1.68M1.4%US$54.4MSep 30, 2026
General Catalyst Group Management, LLC1.6M1.3%US$51.7MSep 30, 2026
General Atlantic, L.P.1.54M1.2%US$49.7MSep 30, 2026
JPMorgan1.06M0.86%US$33.9MSep 30, 2026
Geode Capital1M0.81%US$32.5MSep 30, 2026
Foresite Capital Management VI LLC999K0.81%US$32.3MSep 30, 2026
Catalio Capital Management, LP824K0.67%US$26.6MSep 30, 2026
T. Rowe Price767K0.62%US$24.8MSep 30, 2026
AllianceBernstein765K0.62%US$24.7MSep 30, 2026
State Street758K0.61%US$24.5MSep 30, 2026
Logos Global Management LP750K0.61%US$24.2MSep 30, 2026
Blue Pool Management Ltd.651K0.53%US$21MSep 30, 2026
Casdin Capital, LLC646K0.52%US$20.8MSep 30, 2026
Venrock Adviser, LLC625K0.51%US$20.2MSep 30, 2026
Goldman Sachs602K0.49%US$19.5MSep 30, 2026
Rock Springs Capital Management LP577K0.47%US$18.6MSep 30, 2026
Samsara Biocapital, LLC556K0.45%US$18MSep 30, 2026
Baker Bros. Advisors LP500K0.40%US$16.1MSep 30, 2026
Bellevue Group AG500K0.40%US$16.1MSep 30, 2026
Franklin Templeton449K0.36%US$13.6MSep 30, 2026
Marshall Wace, LLP445K0.36%US$14.4MSep 30, 2026
Sun Life365K0.30%US$11.8MSep 30, 2026
ICONIQ Capital, LLC350K0.28%US$11.3MSep 30, 2026
Schwab329K0.27%US$10.6MSep 30, 2026
Northern Trust298K0.24%US$9.63MSep 30, 2026
Kynam Capital Management, LP250K0.20%US$8.07MSep 30, 2026
Federated Hermes, Inc.246K0.20%US$7.93MSep 30, 2026
UBS212K0.17%US$6.84MSep 30, 2026
Manufacturers Life Insurance Company, The203K0.16%US$6.55MSep 30, 2026
Ameriprise151K0.12%US$4.87MSep 30, 2026
Bank of America103K0.08%US$3.34MSep 30, 2026
BNY102K0.08%US$3.31MSep 30, 2026
Driehaus Capital Management LLC100K0.08%US$3.23MSep 30, 2026
Nuveen90,7860.07%US$2.93MSep 30, 2026
Two Sigma67,0000.05%US$2.16MSep 30, 2026

This page holds 50 of 123 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.12M0.91%US$30.7MJun 30, 2026
Vanguard Small-Cap Index Fund808K0.65%US$22.1MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.487K0.39%US$13.3MJun 30, 2026
JPMorgan Small Cap Growth Fund480K0.39%US$13.1MJun 30, 2026
AB Small Cap Growth Portfolio330K0.27%US$9.03MJun 30, 2026
Janus Henderson Global Life Sciences Fund313K0.25%US$8.57MJun 30, 2026
Vanguard Small-Cap Value Index Fund256K0.21%US$7MJun 30, 2026
Vanguard Small-Cap Growth Index Fund240K0.19%US$6.56MJun 30, 2026
Franklin Small Cap Growth Fund156K0.13%US$5.31MJul 31, 2026
JPMorgan Small Cap Blend Fund155K0.12%US$4.23MJun 30, 2026
All 32 holders
HolderSharesOf the companyValueAs of
Federated Hermes Kaufmann Fund152K0.12%US$5.15MJul 31, 2026
Small Cap Core Portfolio129K0.10%US$3.53MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.120K0.10%US$3.28MJun 30, 2026
SmallCap Growth Fund I100K0.08%US$3.4MJul 31, 2026
Franklin Biotechnology Discovery Fund93,0100.08%US$3.16MJul 31, 2026
Federated Hermes Kaufmann Small Cap Fund91,5000.07%US$3.11MJul 31, 2026
Fidelity Blue Chip Growth Fund89,5810.07%US$3.04MJul 31, 2026
MFS New Discovery Series79,4790.06%US$2.18MJun 30, 2026
Fidelity Blue Chip Growth ETF66,1500.05%US$2.25MJul 31, 2026
T. Rowe Price Health Sciences Portfolio30,3580.02%US$831KJun 30, 2026
Vanguard Balanced Index Fund19,0820.02%US$522KJun 30, 2026
Fidelity Blue Chip Growth K6 Fund18,6090.02%US$632KJul 31, 2026
AVIP AB Small Cap Portfolio17,4170.01%US$477KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund16,8800.01%US$462KJun 30, 2026
Fidelity Series Blue Chip Growth Fund15,0890.01%US$513KJul 31, 2026
Health Sciences Trust10,131<0.01%US$277KJun 30, 2026
EQ/T.Rowe Price Health Sciences Portfolio7,141<0.01%US$195KJun 30, 2026
AB Small Cap Growth Portfolio6,296<0.01%US$172KJun 30, 2026
Federated Hermes Kaufmann Fund II3,200<0.01%US$87,584Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund1,315<0.01%US$35,992Jun 30, 2026
MFS Global Alternative Strategy Fund769<0.01%US$26,131Jul 31, 2026
Fidelity Small Cap Growth K6 Fund1<0.01%US$34Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Ra Capital Management, L.P.
Director, 10% owner
Buy47,250USD 29.77US$1.41MJul 22, 2026
Ra Capital Management, L.P.
Director, 10% owner
Buy21,696USD 27.96US$607KJul 21, 2026
Ra Capital Management, L.P.
Director, 10% owner
Buy6,504USD 29.17US$190KJul 21, 2026
Ra Capital Management, L.P.
Director, 10% owner
Buy37,723USD 30.00US$1.13MJul 21, 2026
Ra Capital Management, L.P.
Director, 10% owner
Buy98,433USD 27.13US$2.67MJul 20, 2026
Ra Capital Management, L.P.
Director, 10% owner
Buy32,987USD 27.72US$914KJul 20, 2026
Sebulsky Alan
Director
Buy5,000USD 26.00US$130KJun 15, 2026
Sebulsky Alan
Director
Buy4,065USD 27.10US$110KJun 15, 2026
Sebulsky Alan
Director
Buy8,435USD 27.67US$233KJun 12, 2026
Soleus Capital Group, LLC
10% owner
Buy375,000USD 20.00US$7.5MJun 11, 2026
All 14 trades
TradeTradeSharesPriceValueDate
Soleus Capital Group, LLC
10% owner
Buy125,000USD 20.00US$2.5MJun 11, 2026
Sebulsky Alan
Director
Buy12,500USD 20.00US$250KJun 11, 2026
RA Capital Nexus Fund III, L.P.
Director
Buy19,728,353USD 20.00US$395MJun 11, 2026
RA Capital Nexus Fund III, L.P.
Director
Buy1,460,397USD 20.00US$29.2MJun 11, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.23.80%28.9MJun 11, 2026Schedule 13D
FMR LLC8.50%10.3MJun 30, 2026Schedule 13G
ARCH Venture Fund XII, L.P.5.30%6.41MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Jun 9, 2026
Alexis Borisy
Other companies: Revolution Medicines, Inc. (Director · Since at least Jun 26, 2025); Blueprint Medicines Corp (Director · Since at least Jun 18, 2025); Relay Therapeutics, Inc. (Director · Since at least Jun 6, 2025); Tango Therapeutics, Inc. (Director · Since at least Jun 5, 2025)
Lead Independent Director; Chairman, Nextech Invest; Chairman, Curie.Bio · Since at least Jun 9, 2026
Barbara Weber
Other companies: Tango Therapeutics, Inc. (Director, Executive Chair, Director · Since at least Aug 10, 2021); OPY Acquisition I Corp (Director · Oct 26, 2021 – Oct 26, 2021 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Oct 8, 2024 · Past)
Director · Since at least Jun 9, 2026
Krishna Yeshwant
Other companies: Verve Therapeutics Inc (Director · Since at least Jun 16, 2021); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Foundation Medicine Inc (Director · Jun 16, 2016 – Jul 31, 2018 · Past)
Director · Since at least Jun 9, 2026
Craig L. Tendler
Other companies: TuHURA Biosciences, Inc. (Director · Since at least Mar 10, 2025)
Director · Since at least Aug 22, 2026
Richard Klausner
Other companies: Lyell Immunopharma, Inc. (Director · Since at least Jun 8, 2021)
Director · Since at least Jun 9, 2026
Rick Klausner
Other companies: Lyell Immunopharma, Inc. (Founder & Chairman of the Board · Since at least Jun 9, 2025)
Founder and Chief Scientist Altos Labs, Inc. · Since at least Nov 4, 2026
Alan M. SebulskyPresident, Apothecary Capital Management, Inc · Since at least Jun 16, 2026
Edward M FitzgeraldDirector · Since at least Jun 11, 2026
Hannah WalterEnterprise Strategic Operations, Chief of Staff to the CEO · Since at least Nov 4, 2026
All 21 people
PersonSeat
Helen HoChief Business and Strategy Officer · Since at least Jun 9, 2026
John McGeeScientific Co-Founder and Executive Vice President, Head of Platform · Since at least Nov 4, 2026
Jonathan HurovExecutive Vice President, Discovery Biology · Since at least Nov 4, 2026
Kristen StantsChief People Officer · Since at least Nov 4, 2026
Marie NguyenSenior Vice President, Head of Clinical Development · Since at least Nov 4, 2026
Markus HaeberleinExecutive Vice President, Discovery Science · Since at least Nov 4, 2026
Mathai MammenChairman, CEO and President · Since at least Nov 3, 2026
Rohin MhatreChief Technical Operations Officer · Since at least Nov 4, 2026
Sheryl JacobsSenior Vice President, Development Operations · Since at least Nov 4, 2026
Teresa JurgensenExecutive Vice President, General Counsel · Since at least Nov 4, 2026
Thomas KotarakosChief Financial Officer · Since at least Jun 9, 2026

Open People

Log in to ask 6ix AI your own questions about Parabilis Medicines, Inc.